RADNOR, Pa., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the fourth quarter and full year of 2025 before market open on Thursday, February 26th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in ...

Core Insights - Certara, Inc. has appointed Jon Resnick as the new CEO effective January 1, 2026, succeeding William Feehery, who will transition to an advisory role [1][3] - The company reaffirms its financial outlook for the full year 2025 as previously disclosed [4] Leadership Transition - Jon Resnick brings over 20 years of experience from IQVIA, where he held various leadership roles, including President of the U.S. and Canada regional business [2][3] - William Feehery has been credited with guiding Certara through its successful IPO and reinforcing its position as a global leader in biosimulation [4] Company Strategy and Vision - Resnick expressed enthusiasm about leading Certara, emphasizing the company's unique position in drug discovery and development through AI, data, and simulation technologies [3] - The company serves over 2,400 clients, including biopharmaceutical companies and regulatory agencies across 70 countries, highlighting its extensive market reach [5]

Core Viewpoint - Certara, Inc. will release its financial results for Q3 2025 on November 6, 2025, after market close, followed by a conference call to discuss the results [1]. Company Overview - Certara is a global leader in biosimulation, utilizing software, technology, and services to enhance drug discovery and development [3]. - The company serves over 2,400 clients, including biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries [3]. Event Details - A conference call will be held at 5:00 PM ET on the same day as the financial results release, and investors must register online to participate [1]. - It is recommended that investors register at least one day in advance [1]. - A live and archived webcast of the event will be available on Certara's website [2].

Core Viewpoint - Certara, Inc. will release its financial results for Q2 2025 on August 6, 2025, after market close, followed by a conference call at 5:00 PM ET to discuss the results [1]. Company Overview - Certara is a global leader in model-informed drug development, utilizing biosimulation software, technology, and services to enhance traditional drug discovery and development [3]. - The company serves over 2,400 clients, including biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries [3]. Investor Information - Investors interested in the conference call must register online, with a recommendation to do so at least one day in advance [1]. - A live and archived webcast of the conference call will be available on the "Investors" section of Certara's website [2]. Contact Information - Investor Relations contact is David Deuchler from Gilmartin Group [4]. - Media contact is Alyssa Horowitz [4].

Core Viewpoint - Certara, Inc. has reported strong preliminary financial results for Q1 2025, with significant growth in revenue and bookings, and has reiterated its full-year guidance for 2025 [2][6]. Financial Performance - Expected revenue for Q1 2025 is $106.0 million, a 10% increase from $96.7 million in Q1 2024 [7]. - Software revenue is projected at $46.4 million, up 18% from $39.3 million in the same quarter last year [7]. - Services revenue is expected to be $59.6 million, reflecting a 4% growth from $57.3 million in Q1 2024 [7]. - Total bookings for Q1 2025 are anticipated to be $118.0 million, a 12% increase from $105.8 million in Q1 2024 [7]. - Adjusted EBITDA is estimated to be in the range of $33-$35 million, representing a growth of 13-20% compared to $29.1 million in Q1 2024 [7]. Full-Year Guidance - The company maintains its full-year 2025 revenue guidance in the range of $415 million to $425 million [8]. - Adjusted EBITDA margin for the full year is expected to be between 30-32% [8]. - Adjusted diluted earnings per share is projected to be in the range of $0.42 - $0.46 [8]. Strategic Developments - Arsenal Capital Partners has agreed to a one-year lock-up on shares acquired from EQT, indicating continued support for Certara's growth [3][6]. - Certara is actively pursuing a strategic evaluation of its regulatory services business, engaging in preliminary discussions with external parties [9]. Share Repurchase Program - The Board of Directors has authorized a stock repurchase program allowing for the repurchase of up to $100 million of outstanding common stock, reflecting confidence in the company's strategy [2][3].